MARKET

ENGN

ENGN

enGene Therapeutics Inc
NASDAQ
1.665
-0.055
-3.20%
Opening 09:51 11/18 EST
OPEN
1.710
PREV CLOSE
1.720
HIGH
1.785
LOW
1.665
VOLUME
155.54K
TURNOVER
--
52 WEEK HIGH
12.25
52 WEEK LOW
1.400
MARKET CAP
111.58M
P/E (TTM)
-0.8008
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENGN last week (1109-1113)?
Weekly Report · 2d ago
enGene: Downgrading To 'Sell' On Non-Competitive Efficacy Detalimogene For NMIBC
Seeking Alpha · 4d ago
Leerink Partners Upgrades enGene Therapeutics to Outperform from Market Perform
NASDAQ · 4d ago
Leerink upgrades enGene to Outperform as worst-case scenario off the table
TipRanks · 5d ago
enGene Holdings (ENGN) Receives a Hold from Guggenheim
TipRanks · 5d ago
enGene Therapeutics Price Target Announced at $5.00/Share by Leerink Partners
Dow Jones · 5d ago
enGene Therapeutics Raised to Outperform From Market Perform by Leerink Partners
Dow Jones · 5d ago
Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target
Benzinga · 5d ago
More
About ENGN
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs. The Company's lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene at high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene is being developed using its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).

Webull offers enGene Therapeutics Inc stock information, including NASDAQ: ENGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGN stock methods without spending real money on the virtual paper trading platform.